M. Chicarelli

发表

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

J. Blake, J. Christensen, B. Brandhuber, 2018, ACS medicinal chemistry letters.

Characterization of a Novel Glucokinase Activator in Rat and Mouse Models

P. Coward, M. McVean, M. Véniant, 2014, PloS one.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

J. Blake, J. Christensen, G. Vigers, 2020 .

Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo.

S. Gross, J. Blake, K. Davies, 2011, Oncology research.

C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

P. Coward, Jaehyeon Park, M. Véniant, 2014, ACS medicinal chemistry letters.

Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance

S. Winski, J. Sachs, K. Bouhana, 2021, Blood.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.

J. Blake, Jianping Yin, Weiru Wang, 2014, Bioorganic & medicinal chemistry letters.

Identification of a new class of glucokinase activators through structure-based design.

K. Condroski, W. deWolf, W. Voegtli, 2013, Journal of medicinal chemistry.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

G. Vigers, J. Gaudino, Jennifer N. Otten, 2020, Journal of medicinal chemistry.

C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

P. Coward, Jaehyeon Park, M. Véniant, 2014, ACS medicinal chemistry letters.